ATE465414T1 - Zwitterkristall aus menschlicher papillomavirus- e2-transaktivierungsdomäne und einem inhibitor sowie roentgenstrukturkoordinaten, die die inhibitorbindende tasche definieren - Google Patents

Zwitterkristall aus menschlicher papillomavirus- e2-transaktivierungsdomäne und einem inhibitor sowie roentgenstrukturkoordinaten, die die inhibitorbindende tasche definieren

Info

Publication number
ATE465414T1
ATE465414T1 AT06012247T AT06012247T ATE465414T1 AT E465414 T1 ATE465414 T1 AT E465414T1 AT 06012247 T AT06012247 T AT 06012247T AT 06012247 T AT06012247 T AT 06012247T AT E465414 T1 ATE465414 T1 AT E465414T1
Authority
AT
Austria
Prior art keywords
inhibitor
tad
hpv
binding pocket
complex
Prior art date
Application number
AT06012247T
Other languages
English (en)
Inventor
Dale R Cameron
Jacques Archambault
Christiane Yoakim
Peter White
Yong Wang
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of ATE465414T1 publication Critical patent/ATE465414T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Laminated Bodies (AREA)
AT06012247T 2001-07-12 2002-07-12 Zwitterkristall aus menschlicher papillomavirus- e2-transaktivierungsdomäne und einem inhibitor sowie roentgenstrukturkoordinaten, die die inhibitorbindende tasche definieren ATE465414T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30441201P 2001-07-12 2001-07-12

Publications (1)

Publication Number Publication Date
ATE465414T1 true ATE465414T1 (de) 2010-05-15

Family

ID=23176405

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06012247T ATE465414T1 (de) 2001-07-12 2002-07-12 Zwitterkristall aus menschlicher papillomavirus- e2-transaktivierungsdomäne und einem inhibitor sowie roentgenstrukturkoordinaten, die die inhibitorbindende tasche definieren
AT02745024T ATE343588T1 (de) 2001-07-12 2002-07-12 Zwitterkristall aus humaner papillomavirus-e2- transaktivierungsdomäne und einem inhibitor sowie roentgen-struktur-koordinaten, die die inhibitorbindende tasche definieren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02745024T ATE343588T1 (de) 2001-07-12 2002-07-12 Zwitterkristall aus humaner papillomavirus-e2- transaktivierungsdomäne und einem inhibitor sowie roentgen-struktur-koordinaten, die die inhibitorbindende tasche definieren

Country Status (14)

Country Link
US (1) US7167801B2 (de)
EP (2) EP1409525B1 (de)
JP (1) JP4602665B2 (de)
AT (2) ATE465414T1 (de)
AU (1) AU2002317122B2 (de)
CA (1) CA2448482C (de)
DE (2) DE60236114D1 (de)
DK (2) DK1695980T3 (de)
ES (2) ES2274051T3 (de)
HU (1) HUP0402069A3 (de)
IL (2) IL159150A0 (de)
MX (1) MXPA04000271A (de)
NZ (1) NZ531068A (de)
WO (1) WO2003006495A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1627323A4 (de) * 2003-05-06 2008-04-09 New Century Pharmaceuticals Albumin-bindestellen zur bewertung von medikamentenwechselwirkungen und verfahren zur bewertung oder entwicklung von medikamenten auf der basis ihrer albumin-bindeeigenschaften
DK1633861T3 (da) * 2003-05-26 2010-03-22 Biotie Therapies Corp Krystallinsk VAP-1 og anvendelser deraf
EP1684705A4 (de) * 2003-11-03 2008-02-20 New Century Pharmaceuticals Albumin-bindungsstellen zur beurteilung von arzneimittelwechselwirkungen und verfahren zur beurteilung oder zum entwurf von arzneimitteln auf basis ihrer albuminbindungseigenschaften
US20090118301A1 (en) * 2007-11-02 2009-05-07 Arbor Vita Corporation Compositions and Methods for Treating Cancer
CN112891520A (zh) * 2021-04-13 2021-06-04 吉林省国大生物工程有限公司 一种预防和控制人乳头瘤病毒感染（hpv）的活性生物蛋白的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU671808B2 (en) * 1991-10-11 1996-09-12 Chiron Corporation Methods and compositions for identifying inhibitors of papilloma virus replication
US6306580B1 (en) 1998-05-01 2001-10-23 Boehringer Ingelheim (Canada) Ltd. Preparation of human papillomavirus E1 having helicase activity and method therefor
DE69812597D1 (de) 1998-06-30 2003-04-30 Deutsches Krebsforsch Peptide zur Inhibition von HPV E7 Proteinen
WO2000075182A1 (fr) * 1999-06-04 2000-12-14 Akira Kaji Cristal de proteine du facteur de recyclage ribosomique (rrf) et son application sur la base de donnees de structure tridimensionnelles provenant du cristal
GB9921938D0 (en) 1999-09-17 1999-11-17 Univ York Target for antiviral therapy
EP1232253A2 (de) * 1999-11-16 2002-08-21 Vertex Pharmaceuticals Incorporated Caspase-7 enthaltende kristallisierbare zusammensetzungen
IL156191A0 (en) 2000-12-18 2003-12-23 Boehringer Ingelheim Ca Ltd Inhibitors of papilloma virus

Also Published As

Publication number Publication date
US20030082769A1 (en) 2003-05-01
DE60215658T2 (de) 2007-12-27
ATE343588T1 (de) 2006-11-15
EP1409525A2 (de) 2004-04-21
JP4602665B2 (ja) 2010-12-22
EP1409525B1 (de) 2006-10-25
HUP0402069A2 (hu) 2005-01-28
JP2005512954A (ja) 2005-05-12
HUP0402069A3 (en) 2012-09-28
WO2003006495A3 (en) 2003-07-31
IL159150A (en) 2009-09-01
AU2002317122B2 (en) 2007-03-15
DK1695980T3 (da) 2010-08-02
ES2342309T3 (es) 2010-07-05
NZ531068A (en) 2006-06-30
DE60215658D1 (de) 2006-12-07
US7167801B2 (en) 2007-01-23
EP1695980A2 (de) 2006-08-30
WO2003006495A2 (en) 2003-01-23
CA2448482A1 (en) 2003-01-23
EP1695980B1 (de) 2010-04-21
MXPA04000271A (es) 2005-03-07
EP1695980A3 (de) 2006-09-06
ES2274051T3 (es) 2007-05-16
DK1409525T3 (da) 2007-02-05
IL159150A0 (en) 2004-06-01
CA2448482C (en) 2011-12-06
DE60236114D1 (de) 2010-06-02

Similar Documents

Publication Publication Date Title
BR0308385A (pt) Cristais de ácido (met) acrìlico e processo para produzir e purificar ácido (met) acrìlico aquoso
ATE381963T1 (de) Verfahren zur herstellung von gereinigten partikeln
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
ATE448225T1 (de) Aza-bicycloalkylether und deren verwendung als alpha7-nachr agonisten
JPH06505497A (ja) 血小板凝集阻害剤として有用なフェニルアミジン誘導体類
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
KR930004276A (ko) 치환된 헤테로사이클류
EP1288209A4 (de) Methode zur reinigung von propylenoxid
BR9909358A (pt) Composto, composição farmacêutica, e, processo para prevenção ou alìvio de complicações crÈnicas decorrentes de diabetes melito
ATE206122T1 (de) Verbindungen, die als antiproliferative mittel und als garft inhibitoren verwendbar sind
CY1106721T1 (el) Μεθοδος παρασκευης υψηλης καθαροτητας περινδοπριλης και ενδιαμεσα χρησιμα στη συνθεση
DE69934595D1 (de) Verwendung von verbindungen die alpha2-antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle
ATE279441T1 (de) Verfahren zur herstellung von genetisch veränderten lymphozyten vorläuferzellen von wirbeltieren und deren gebrauch zur produktion von heterologen bindeproteinen
TW200604204A (en) High-purity trimethylaluminum and method for purifying trimethylaluminum
ATE465414T1 (de) Zwitterkristall aus menschlicher papillomavirus- e2-transaktivierungsdomäne und einem inhibitor sowie roentgenstrukturkoordinaten, die die inhibitorbindende tasche definieren
DE59902281D1 (de) Verfahren zur herstellung eines aus einzelnen schichten bestehenden laminats
DE60316791D1 (de) Verfahren zur aufreinigung von lanzoprazol
DE60208784D1 (de) Clathrat von azithromycin-hydrat mit 1,2-propylenglykol, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zusammensetzung
DE3580382D1 (de) Monoklonale antikoerper gegen alpha-2 interferon und hybridomas, die solche antikoerper produzieren.
DE60213649D1 (de) Verwendung von molekularsieben zur umsetzung von sauerstoffverbindungen in leichte olefine
ATE472337T1 (de) Pharmazeutische zusammensetzung aus f(ab) 2- fragmenten von antikörpern und verfahren zu ihrer herstellung
DE60005304D1 (de) Methode zur reinigung und abtrennung von (2s,3s)- oder (2r,3s)-halohydrinderivaten
DE69522960D1 (de) Verfahren zur herstellung von substituierten 4-ethylpiperidinen
ATE269858T1 (de) Kristallines oder kristallisiertes säureadditionssalz von losartan und verfahren zur reinigung von losartan
NZ516235A (en) Method for purification of proteins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1695980

Country of ref document: EP